PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Shown promise in treatment of NYHA functional class II CHF in both uncontrolled and controlled trials; reviews of placebo-controlled trials report subjective and objective improvement in mild forms (NYHA I-III) [PMID:11887407, PMID:24459528]
A single 160-mg dose showed no significant differences in QTc, PR, or QRS intervals compared to placebo [PMID:29672935]
Showed promising effects on anxiety in animal models [PMID:33480339]
Reviews of placebo-controlled trials report improvement in hypertension and hyperlipidemia [PMID:24459528]
Safety & adverse effects
Pregnancy & lactation
Evidence summary
PubMed sources
- 1.PMID: 33480339 (2022) — Anti-anxiety Properties of Selected Medicinal Plants. · Current pharmaceutical biotechnology
- 2.PMID: 11887407 (2002) — Hawthorn: pharmacology and therapeutic uses. · American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
- 3.PMID: 27655074 (2018) — Phytochemical and Pharmacological Activity Profile of Crataegus oxyacantha L. (Hawthorn) - A Cardiotonic Herb. · Current medicinal chemistry
- 4.PMID: 16011292 (2005) — [Crataegus oxyacantha (aubepine) in the use as herb medicine in France]. · Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
- 5.PMID: 30058501 (2019)